StockNews.com assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Free Report) in a report released on Friday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Genocea Biosciences Price Performance
The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35. Genocea Biosciences has a 52-week low of $0.00 and a 52-week high of $0.00. The stock has a market capitalization of $6,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.61.
Genocea Biosciences Company Profile
Further Reading
- Five stocks we like better than Genocea Biosciences
- What Are Growth Stocks and Investing in Them
- Celebrate July 4th with These Red, White, & Blue Chip Stocks
- 5 Top Rated Dividend Stocks to Consider
- AbbVie Stock: A Perfect Dip for Investors to Buy
- What Investors Need to Know About Upcoming IPOs
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.